Anixa Biosciences, Inc. — Form 10-Q summary
Reporting period: Third quarter and nine months ended July 31, 2023. Unaudited results; dollar amounts below are in millions unless noted.
Business context
Anixa is a clinical-stage biotechnology company developing cancer vaccines and CAR-T therapies. It also conducts limited legacy patent licensing. It reported no revenue from its vaccine or therapeutic programs. The COVID-19 antiviral program was paused in March 2023.
Financial performance and position
| Metric | Three months ended July 31, 2023 | Three months ended July 31, 2022 | Nine months ended July 31, 2023 | Nine months ended July 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0.210 | $0 |
| Operating costs and expenses | $2.844 | $2.797 | $8.170 | $10.266 |
| Operating loss | $(2.844) | $(2.797) | $(7.960) | $(10.266) |
| Interest income | $0.296 | $0.022 | $0.751 | $0.024 |
| Net loss attributable to common shareholders | $(2.511) | $(2.746) | $(7.121) | $(10.119) |
| Basic and diluted loss per share | $(0.08) | $(0.09) | $(0.23) | $(0.33) |
Revenue was a one-time legacy patent license payment of $0.210 million; the filing reports no Q3 revenue. Gross margin is not meaningful given the absence of quarterly revenue and the company’s development-stage business. Nine-month R&D expense was $3.154 million, down from $5.018 million; G&A was $4.855 million, down from $5.248 million. In Q3, R&D was $1.088 million versus $1.445 million, while G&A rose to $1.756 million from $1.352 million.
At July 31, cash and cash equivalents were $3.198 million and short-term investments were $22.336 million, totaling $25.534 million, compared with $29.687 million at October 31, 2022. Total assets were $26.578 million and total liabilities were $1.993 million. The balance sheet reports no borrowings; liabilities primarily comprised accrued expenses and operating lease obligations. Current assets were $26.400 million versus current liabilities of $1.857 million.
For the nine months, operating cash use was $4.240 million, investing cash use was $5.009 million, and financing cash inflow was $0.087 million. Cash and cash equivalents fell by $9.162 million, partly reflecting purchases of short-term investments; cash plus short-term investments declined by approximately $4.153 million. The company had not used its at-the-market program during the period.
Material changes and operating updates
- Nine-month net loss attributable to common shareholders narrowed to $7.121 million from $10.119 million, largely alongside lower operating expenses and substantially higher interest income. Q3 operating loss increased slightly, while net loss improved, principally due to higher interest income.
- The company said lower R&D costs reflected reduced antiviral-program spending and lower share-based compensation. G&A decreased year over year for nine months but increased in Q3, including higher employee, director, investor-relations, and consultant costs.
- The breast cancer vaccine Phase 1a expanded cohorts had completed vaccination by August 2023; blood samples were being analyzed. Management anticipated presenting data in December 2023 and planned further dose cohorts. Recruitment had begun for Phase 1b and Phase 1c.
- In the ovarian cancer CAR-T Phase 1 study, the third patient was treated in August 2023 at the initial dose level; treatment appeared well-tolerated. Management expected to begin enrolling the next, higher-dose cohort in Q4 2023.
Outlook, risks, and contingencies
Management stated, based on information available September 6, 2023, that existing cash, cash equivalents, short-term investments, and expected cash flows should fund activities for at least the next 12 months. It cautioned that projections may differ from actual results and that additional capital may be needed; financing may not be available on acceptable terms and equity or convertible-debt financing could dilute shareholders. The company may sell up to $100 million of common stock under its ATM program.
Anixa does not expect near-term revenue from its current vaccine or therapy programs; potential licensing may take years, may depend on successful clinical results, or may not occur. The antiviral program remains paused due to inadequate oral bioavailability and the company’s view that further delivery-method research would divert resources. Patent enforcement litigation is part of its legacy activity; the filing reports no other material pending legal proceedings expected to materially harm results or financial condition. Management reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether vaccine and CAR-T trial enrollment, dose escalation, safety monitoring, and planned data disclosures proceed as anticipated.
- Whether cash burn and investment balances support the stated 12-month runway, and whether additional financing or ATM sales become necessary.
- Whether the company can generate recurring revenue or licensing income; current reported revenue was limited to a one-time legacy license payment.
- The potential dilution from outstanding options and any future equity financing; common shares outstanding were 31,017,770 at July 31, 2023.